Does Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam Interact with Cyp3a Inducers?
Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and Cyp3a Inducers have a major drug interaction according to U.S. FDA drug labeling data. CYP3A inducers increase clearance of elvitegravir and cobicistat, resulting in decreased plasma concentrations and potential loss of therapeutic effect or resistance. The mechanism involves induction of cyp3a metabolism. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam Class
- Cytochrome P450 3A Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and Cyp3a Inducers occurs because induction of cyp3a metabolism. Clinically, this means cyp3a inducers increase clearance of elvitegravir and cobicistat, resulting in decreased plasma concentrations and potential loss of therapeutic effect or resistance. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and your doctor is considering prescribing Cyp3a Inducers (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider